ClinicalTrials.gg
RecruitingNCT01306019Updated Nov 12, 2026

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

A Phase 1/2 interventional study of Campath and Palifermin in X-linked Severe Combined Immunodeficiency (XSCID), sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 1 site in United States. Open to male participants aged 2 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2012; still recruiting 14 years 1 month later.
Updated Oct 27, 2026Interventions changedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
2 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. X-Linked Combined Immunodeficiency Diseases · United States.

Planned enrollment
2nd of 11
40 · median 12
Started
2012
with 1 other
Phase 1/2
8 of 20
3 open now
Registered
12th of 20
by date
Lead sponsor
8 of 20
National Institute of Allergy and Infectious Diseases (NIAID)

Among the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2012, is one of 8 in phase 1/2, and was the 12th registered.

X-Linked Combined Immunodeficiency Diseases

28 studies on the registry are indexed under X-Linked Combined Immunodeficiency Diseases; 9 are open to participants now.

Browse X-Linked Combined Immunodeficiency Diseases studies →

Open to participants now

5 of the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 X-Linked Combined Immunodeficiency Diseases studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 50 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States, or all of them as a file.
02

Study summary

This Phase I/II clinical trial will study the safety and potential benefits of gene therapy for up to 35 people aged 2 to 50 with X-linked severe combined immunodeficiency (XSCID), a rare genetic condition that makes it difficult to fight infections.

The study is for patients with XSCID who have serious immune system problems, including those who continue to experience serious immune complications after a previous stem cell transplant, and who do not have a suitably matched sibling donor. Treatment uses the patient s own blood-forming stem cells, which are collected from the bloodstream. In a laboratory, a specially designed delivery system called a lentiviral vector adds a working copy of the affected gene to these cells to help them produce functioning immune cells.

Before receiving the modified cells, patients will receive a reduced dose of busulfan, a chemotherapy medicine that makes room in the bone marrow for the treated cells. The dose may be further adjusted according to the study protocol, including for patients with significant organ damage. Alemtuzumab (Campath) may also be given when clinically indicated, including to address certain immune problems involving donor T cells from a previous transplant. The modified stem cells will then be returned through a single infusion into a vein.

Researchers will monitor side effects, how well the modified cells survive and produce immune cells, and whether patients develop stronger immune function and better health. The main assessment will occur two years after treatment, with follow-up visits continuing through year five. A separate long-term follow-up study will monitor patients through year 15 for lasting benefits and delayed side effects, including cancer. This treatment is experimental, and its benefits and risks are not yet fully known....

Read the detailed description

This is a non-randomized clinical trial of gene transfer using a self-inactivating, insulated, lentiviral gene transfer vector to treat 35 patients with X-linked severe combined immunodeficiency (XSCID, also called SCID-X1) who are between 2 and 50 years of age; who do not have a tissue matched sibling who can donate bone marrow for a transplant; who may have failed to obtain sufficient benefit from a previous half-tissue matched bone marrow transplant; and who have clinically significant impairment of immunity. A patient's own precursor cells (also called blood stem cells) that give rise in the marrow to blood and immune cells will have been or will be collected from the patient's blood or bone marrow. A patient will not proceed to gene transfer treatment in this protocol until there are at least 3 million blood stem cells per kilogram body weight collected from the patient. At the NIH the patient blood stem cells will be cells collected previously under NIH protocol 94-1-0073 or collected on this protocol. In most cases the harvested blood stem cells are put into frozen storage before use in this protocol. When the patient enrolled in this protocol has the required number of blood stem cells harvested, then the patient's blood stem cells will be grown in tissue culture and exposed to the lentiviral gene transfer vector containing the corrective gene. These gene-corrected blood stem cells will be administered through the patient's vein. To increase engraftment of the corrected blood stem cells, patients will receive a chemotherapy drug called busulfan at a total dose of 6 mg/kilogram body weight (3 mg/kilogram body weight/daily) for two days before the gene transfer treatment. The busulfan dose used in this study is a little more than one-third the dose used in many standard bone marrow transplants. To improve patient safety, those with significant organ damage may receive reduced busulfan dose of a total 4mg/kg with 2mg/kg dose given on Day 1, and dose adjusted on day 2 to achieve AUC of 6000 min*umol/L. Subjects who mobilize poorly (total CD34+ cells \<5 million/kg) may use all their cells for product manufacture without leaving backup aliquot of 1e6/kg.

For patients who have clinical problems related to donor T cell dysregulation, alemtuzumab (Campath) may be administered. Patients will also be given another drug called palifermin that helps prevent the main side effect from the busulfan, which is a type of inflammation of the mouth, stomach and bowels called mucositis. After the gene transfer treatment, patients will be monitored to see if the treatment is safe and whether their immune system improves. Patients will be followed at frequent intervals for the first 2 years, and less frequently thereafter so that the effectiveness in restoration of immune function and the safety of the treatment can be evaluated.

XSCID is a genetic disease caused by defects in common gamma chain, a protein found at the surface of immune cells called lymphocytes and is necessary for their growth and function. XSCID patients cannot make T-lymphocytes necessary to fight infections, and their B-cells fail to make essential antibodies. Without normal T- and B-lymphocyte function, patients develop fatal infections in infancy unless they receive a bone marrow transplant from a healthy donor. The best type of transplant is from a tissue-matched healthy brother or sister, but most XSCID patients do not have a tissue-matched sibling and are treated with a transplant from a parent who is only half- matched by tissue typing. While a half-matched transplant from a parent can be lifesaving for an infant with XSCID, a subset of patients fails to achieve sufficient long lasting restoration of immunity to prevent infections and other chronic problems. Trials of gene transfer treatments using mouse retrovirus vectors for infants with XSCID have been performed and have demonstrated that this type of gene transfer can be an alternate approach for significantly restoring immunity to infants with XSCID. However, among the 18 infants with XSCID benefiting long-term from the gene transfer treatment, 5 developed Tlymphocyte leukemia and 1 died of this leukemia. Furthermore, when older children with XSCID were treated with gene transfer, the restoration of immunity was much less than seen in the infants. These observations of gene transfer treatments using mouse retrovirus vectors to treat infants and older patients with XSCID suggest that safer and more effective vectors were needed, and that there also may be a need to give chemotherapy or other method of conditioning to increase engraftment in the marrow of the gene corrected blood stem cells. Our data and other published studies suggest that lentivectors that are derived from the human immunodeficiency virus and have the properties of our highly modified vector called CL20-4i-EF1alpha- h-gamma-c-OPT have a reduced interaction with nearby genes and therefore less of a tendency to activate genes that may lead to cancer formation. Also, this type of lentivector may work better at getting into blood stem cells.

The purpose of this study is to evaluate the safety and effectiveness of the lentiviral gene transfer treatment at restoring immune function to XSCID patients who are 2 to 50 years of age and have significant impairment of immunity. Early evidence for effectiveness will be defined by appearance and expansion in the circulation of the patient's own gene corrected T-lymphocytes with a functional gamma-c gene and improved laboratory measures of immune function. The primary endpoint for efficacy will be assessed 2 years after treatment and will include these laboratory parameters plus evidence for clinical benefit. Evidence for safety will focus on the maintenance of a diversity of gene marked cells and no occurrence of abnormal patterns of production of blood cells or any leukemia or other cancer. The primary study endpoints for all laboratory and clinical measures of efficacy and safety will occur at 2 years after gene transfer treatment. However, data collection regarding efficacy will occur at frequent intervals during the 2 years leading up to the endpoint analysis, through study completion at 5 years. Safety and efficacy evaluations will continue yearly under a separate NIH study during the long-term follow-up period recommended by the United States FDA for patients participating in gene transfer treatment studies.

03

Conditions studied

  • X-linked Severe Combined Immunodeficiency (XSCID)

Keywords

  • T cell, B cell, NK cell
  • Gene Transfer
  • Peripheral Blood Stem Cells
  • Common Gamma Chain (gamma c)
  • Immune Reconstitution
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
2 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A proven mutation in the common gamma chain gene as defined by direct sequencing of patient DNA
  • No available HLA matched sibling donor as determined before enrollment (HLA typing will be performed prior to enrollment)
  • Must be between 2 and 50 years of age and weigh 10 kg
  • If previously transplanted, must be 18 months post-
  • Expected survival of at least 120 days.
  • Participants of must agree to consistently use highly effective throughout study participation and for at least 2 years post-treatment. Acceptable forms of contraception are:

    --For males: Condoms or other contraception with partner.

  • Documented to be negative for infection by genome PCR
  • The patient must be judged by the primary evaluating physician to have a suitable family and social situation consistent with ability to comply with protocol procedures and the long-term follow-up requirements.
  • Medical lab data (historical) of severe B cell dysfunction (low or absent IgG levels, failed immune response to vaccines); OR demonstrated requirement for intravenous gamma globulin (IVIG) (significant drop over 3 to 6 weeks between peak and trough IgG levels).
  • Must be willing to have blood and tissue samples stored IN ADDITION, patients must satisfy the following Laboratory Criteria AND Clinical Criteria

Laboratory Criteria: (>=1 must be present)

I. CD4+ lymphocytes: absolute number \<= 50% of the lower limit of normal (LLN)

II. CD4+ 5RA+ lymphocytes: absolute number \<= 50% of the LLN OR T-cell receptor excision circles (TRECs) \<= 5% of normal for age.

III. Memory B Cells: absolute number \<= 50% of LLN

IV. Serum IgM\<normal for age

V. NK cells: absolute number \<= 50% of LLN

VI. Lymphocyte proliferative response to each of 2 mitogens, phytohemagglutinin (PHA) and concanavalin A (ConA), is \<= 25% compared with a normal control.

VII. Molecular spectratype analysis- absent or very oligoclonal (1-3 dominant peaks) in >=6 of the 24 VBeta T-cell receptor families.

Clinical Criteria: (>=1 must be present):

I. Infections (not including molluscum, warts or mucocutaneous candidiasis; see vii and viii below):

Three significant new or chronic active infections during the 2 years preceding evaluation for enrollment, with each infection accounting for one criteria.

Infections are defined as an objective sign of infection (fever >38.3 degrees C [101 degrees F] or neutrophilia or pain/redness/swelling or radiologic/ultrasound imaging evidence or typical lesion or histology or new severe diarrhea or cough with sputum production). In addition to one or more of these signs/symptoms of possible infection, there also must be at least 1 of the following criteria as evidence of the attending physician's "intent to treat" a significant infection (a. and b.) or objective evidence for a specific pathogen causing the infection (c.)

  1. Treatment (not prophylaxis) with systemic antibacterial, antifungal or antiviral antibiotics 14 days

    OR

  2. Hospitalization of any duration for infection

    OR

  3. Isolation of a bacteria, fungus, or virus from , skin lesion, blood, nasal washing, bronchoscopy, cerebrospinal fluid or stool likely to be an etiologic agent of infection

II. Chronic pulmonary disease as defined by:

  1. Bronchiectasis by x-ray computerized tomography

    OR

  2. Pulmonary function test (PFT) evidence for restrictive or obstructive disease that is 60% of Predicted for Age

    OR

  3. Pulse oximetry 94% in room air (if patient is too young to comply with performance of PFTs).

III. Gastrointestinal enteropathy:

  1. Diarrhea-watery stools 3 times per day (of at least 3 months duration that is not a result of infection as defined in criterion # i. above)

    OR

  2. Endoscopic evidence (gross and histologic) for enteropathy (endoscopy will only be performed if medically indicated)

    OR

  3. Other evidence of enteropathy or bacterial overgrowth syndrome: including malabsorption of fat-soluble vitamin(s), abnormal D-xylose absorption, abnormal hydrogen breath test, evidence of protein losing enteropathy (for example increasingly high or frequent dosing of intravenous gamma globulin supplement required to maintain blood IgG level).

IV. Poor nutrition: Requires G-tube or intravenous feeding supplement to maintain weight or nutrition.

V. Auto- or allo-immunity: Examples must include objective physical findings that include, but are not limited to any one of alopecia, severe rashes, uveitis, joint pain with redness or swelling or limitation of movement that is not a result of infection, lupus-like lesions, and granulomas (Does not include auto- or allo-immune enteropathy which is criterion iii). Where possible and appropriate, diagnosis will be supported by histopathology or other diagnostic modality.

VI. Failure to grow in height: \<=3rd percentile for age

VII. Skin molluscum contagiosum OR warts (this criterion is satisfied if molluscum consists of 10 lesions or there are two or more lesions at each of two or more widely separated anatomic sites; or there are 3 warts at different anatomic sites at the same time; or the patient has both molluscum and warts)

VIII. Mucocutaneous candidiasis (chronic oral thrush or candida esophagitis or candida intertriginous infection or candida nail infections; must be culture positive to satisfy this criterion)

IX. Hypogammaglobulinemia: requires regular IgG supplementation

Criteria for eligibility for Campath (alemtuzumab):

Evidence of organ disease attributable to T cell dysregulation, for example, elevated transaminases.

Exclusion criteria

EXCLUSION CRITERIA:

  • Any current or pre-existing hematologic
  • Documented -1 infection
  • Documented active infection
  • Childhood malignancy (occurring before 18 years of age) in the patient or a first degree relative, or previously diagnosed known genotype of the subject conferring a predisposition to cancer (no DNA or other testing for cancer predisposition genes will be performed as part of the screen for this protocol)
  • Unwilling to submit their information as part of the alemtuzumab (Campath(R)) Distribution Program application or the Distribution Program committee has determined the participant is not qualified to receive alemtuzumab.

NOTE: Alemtuzumab (Campath) is no longer distributed commercially. To receive product, the physician must contact the program for the participant. If Campath use is indicated and the participant is not willing to consent to submit their info (demographics, contact information, and rationale for use) to the program such that we can obtain the drug, then the participant will not undergo gene therapy and will be withdrawn.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    cohort a

    First 8 Patients Treated

    Drug: Palifermin · Drug: Busulfan · Biological: Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector

  • Other
    cohort b

    Patients 9 and Beyond

    Drug: Campath · Drug: Palifermin · Drug: Busulfan · Biological: Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector

Interventions

  • DrugAlemtuzumabStudies of AlemtuzumabAlemtuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    May be administered subcutaneously Days -21 through Day -19 in patients who demonstrate evidence of donor T cell dysregulation

  • DrugFibroblast Growth Factor 7Studies of Fibroblast Growth Factor 7Fibroblast Growth Factor 7 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mucositis prophylaxis commenced- Infusion of keratinocyte growth factor (palifermin) at 60 mcg/kg/day before (Days -6 to Day -4) administration of busulfan and (Days +1 to +3) post-busulfan administration

  • 3mg/kg per day with drug levels obtained on Day -3. Busulfan dose on day -2 will be adjusted (if busulfan AUC result is available) to achieve targeted busulfan AUC 4500 min\*umol/L/day. Dose reduction to a total dose of 4mg/kg (target AUC 6000 min\*umol/L/day) may be offered to patients with significant organ damage

  • BiologicalEx vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector

    Transduced cell product administered intravenously over approximately 30 minutes by authorized licensed personnel consistent with NIH Clinical Center Department of Transfusion Medicine's standard operating procedures for cellular products.

06

What researchers measure

Primary outcomes

  1. Early evidence for efficacy will be defined by appearance and expansion in the circulation of autologous transduced T-lymphocytes with functional gmama-c and improved laboratory measures of immune function in the interim evaluation of these para...

    successful, partial successful or failure

    Time frame: 1 year

Secondary outcomes

  1. evidence for efficacy at 2 years after treatment will include these same laboratory parameters measured at the 2 year time point plus evidence for clinical benefit

    maintenance of polyclonality of vector marking, the lack of emergence of a dominant gene marked clone in any hematopoietic lineage, and no occurrence of either hematologic dysplasia or any leukemia or other cancer resulting from the gene transfer

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Publications

  • Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K, Chatters SJ, de Ridder D, Gilmour KC, Adams S, Thornhill SI, Parsley KL, Staal FJ, Gale RE, Linch DC, Bayford J, Brown L, Quaye M, Kinnon C, Ancliff P, Webb DK, Schmidt M, von Kalle C, Gaspar HB, Thrasher AJ. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008 Sep;118(9):3143-50. doi: 10.1172/JCI35798. PubMed 18688286 ↗
  • Kang EM, Choi U, Theobald N, Linton G, Long Priel DA, Kuhns D, Malech HL. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood. 2010 Jan 28;115(4):783-91. doi: 10.1182/blood-2009-05-222760. Epub 2009 Dec 1. PubMed 19965657 ↗
  • Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, Mahlaoui N, Kiermer V, Mittelstaedt D, Bellesme C, Lahlou N, Lefrere F, Blanche S, Audit M, Payen E, Leboulch P, l'Homme B, Bougneres P, Von Kalle C, Fischer A, Cavazzana-Calvo M, Aubourg P. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009 Nov 6;326(5954):818-23. doi: 10.1126/science.1171242. PubMed 19892975 ↗
  • De Ravin SS, Liu S, Sweeney CL, Brault J, Whiting-Theobald N, Ma M, Liu T, Choi U, Lee J, O'Brien SA, Quackenbush P, Estwick T, Karra A, Docking E, Kwatemaa N, Guo S, Su L, Sun Z, Zhou S, Puck J, Cowan MJ, Notarangelo LD, Kang E, Malech HL, Wu X. Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency. Nat Commun. 2022 Jun 28;13(1):3710. doi: 10.1038/s41467-022-31344-x. PubMed 35764638 ↗

Individual participant data

Plan to share: Undecided — The PI has yet to determine how IPD will be shared.

09

Timeline

10 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2012 (actual). Primary completion is estimated for Dec 2032, 243 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2011
First posted
Mar 1, 2011
StartActual
Sep 25, 2012
Primary completionEst.
Dec 31, 2032
CompletionEst.
Dec 31, 2032
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
17 inclusion criteria edited, 2 added; 2 exclusion criteria added
What changed in the criteria
Inclusion criteria
  • EditedNo available HLA matched sibling donor as determined before enrollment. (HLA typing will be performed prior to enrollment)
  • EditedMust be between 2 and 50 years of age and weigh greater than or equal to 10 kg
  • EditedIf previously transplanted, must be greater than or equal to 18 months post -HSCT
  • EditedLaboratory Criteria: (greater than or equal to >=1 must be present)
  • EditedCD4+ lymphocytes: absolute number less than or equal to<= 50 percent% of the lower limit of normal (LLN)
  • EditedCD4+ CD45RA+ lymphocytes: absolute number less than or equal to<= 50 percent% of the LLN OR T-cell receptor excision circles (TRECs) less than or equal to<= 5 percent% of normal for age.
  • EditedMemory B Cells: absolute number less than or equal to<= 50 percent% of LLN
  • EditedNK cells: absolute number less than or equal to<= 50 percent% of LLN
  • EditedLymphocyte proliferative response to each of 2 mitogens, phytohemagglutinin (PHA) and concanavalin A (ConA), is <= 25 percent% compared with a normal control.
  • EditedMolecular spectratype analysis- absent or very oligoclonal (1-3 dominant peaks) in greater than or equal to >=6 of the 24 VBeta T-cell receptor families.
  • EditedClinical Criteria: (greater than or equal to >=1 must be present):
  • EditedInfections are defined as an objective sign of infection (fever greater than >38.3 degrees C [101 degrees F] or neutrophilia or pain/redness/swelling or radiologic/ultrasound imaging evidence or typical lesion or histology or new severe diarrhea or cough with sputum production). In addition to one or more of these signs/symptoms of possible infection, there also must be at least 1 of the following criteria as evidence of the attending physician 's "intent to treat" a significant infection (a. and b.) or objective evidence for a specific pathogen causing the infection (c.)
  • EditedTreatment (not prophylaxis) with systemic antibacterial, antifungal or antiviral antibiotics greater than or equal to 14 days
  • EditedPulmonary function test (PFT) evidence for restrictive or obstructive disease that is 60 percent% of Predicted for Age
  • EditedPulse oximetry 94 percent% in room air (if patient is too young to comply with performance of PFTs).
  • EditedDiarrhea-watery stools greater than or equal to 3 times per day (of at least 3 months duration that is not a result of infection as defined in criterion # i. above)
  • EditedFailure to grow in height: less than or equal to <=3rd percentile for age
  • AddedCriteria for eligibility for Campath (alemtuzumab):
  • AddedEvidence of organ disease attributable to T cell dysregulation, for example, elevated transaminases.
Exclusion criteria
  • AddedUnwilling to submit their information as part of the alemtuzumab (Campath(R)) Distribution Program application or the Distribution Program committee has determined the participant is not qualified to receive alemtuzumab.
  • AddedNOTE: Alemtuzumab (Campath) is no longer distributed commercially. To receive product, the physician must contact the program for the participant. If Campath use is indicated and the participant is not willing to consent to submit their info (demographics, contact information, and rationale for use) to the program such that we can obtain the drug, then the participant will not undergo gene therapy and will be withdrawn.
Oct 19, 2026
Interventions
Added Drug: Campath
Oct 27, 2026
Show all 10 updates
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 9, 2026
    Minor edits only
    + 1 other change: description
  3. Nov 5, 2026
    Minor edits only
    + 1 other change: description
  4. Oct 27, 2026
    Interventions Added Drug: Campath
    + 3 other changes: verification date, description and index terms
  5. Oct 22, 2026
    Minor edits only
    + 1 other change: verification date
  6. Oct 19, 2026
    Eligibility 17 inclusion criteria edited, 2 added; 2 exclusion criteria added
    What changed in the criteria
    Inclusion criteria
    • EditedNo available HLA matched sibling donor as determined before enrollment. (HLA typing will be performed prior to enrollment)
    • EditedMust be between 2 and 50 years of age and weigh greater than or equal to 10 kg
    • EditedIf previously transplanted, must be greater than or equal to 18 months post -HSCT
    • EditedLaboratory Criteria: (greater than or equal to >=1 must be present)
    • EditedCD4+ lymphocytes: absolute number less than or equal to<= 50 percent% of the lower limit of normal (LLN)
    • EditedCD4+ CD45RA+ lymphocytes: absolute number less than or equal to<= 50 percent% of the LLN OR T-cell receptor excision circles (TRECs) less than or equal to<= 5 percent% of normal for age.
    • EditedMemory B Cells: absolute number less than or equal to<= 50 percent% of LLN
    • EditedNK cells: absolute number less than or equal to<= 50 percent% of LLN
    • EditedLymphocyte proliferative response to each of 2 mitogens, phytohemagglutinin (PHA) and concanavalin A (ConA), is <= 25 percent% compared with a normal control.
    • EditedMolecular spectratype analysis- absent or very oligoclonal (1-3 dominant peaks) in greater than or equal to >=6 of the 24 VBeta T-cell receptor families.
    • EditedClinical Criteria: (greater than or equal to >=1 must be present):
    • EditedInfections are defined as an objective sign of infection (fever greater than >38.3 degrees C [101 degrees F] or neutrophilia or pain/redness/swelling or radiologic/ultrasound imaging evidence or typical lesion or histology or new severe diarrhea or cough with sputum production). In addition to one or more of these signs/symptoms of possible infection, there also must be at least 1 of the following criteria as evidence of the attending physician 's "intent to treat" a significant infection (a. and b.) or objective evidence for a specific pathogen causing the infection (c.)
    • EditedTreatment (not prophylaxis) with systemic antibacterial, antifungal or antiviral antibiotics greater than or equal to 14 days
    • EditedPulmonary function test (PFT) evidence for restrictive or obstructive disease that is 60 percent% of Predicted for Age
    • EditedPulse oximetry 94 percent% in room air (if patient is too young to comply with performance of PFTs).
    • EditedDiarrhea-watery stools greater than or equal to 3 times per day (of at least 3 months duration that is not a result of infection as defined in criterion # i. above)
    • EditedFailure to grow in height: less than or equal to <=3rd percentile for age
    • AddedCriteria for eligibility for Campath (alemtuzumab):
    • AddedEvidence of organ disease attributable to T cell dysregulation, for example, elevated transaminases.
    Exclusion criteria
    • AddedUnwilling to submit their information as part of the alemtuzumab (Campath(R)) Distribution Program application or the Distribution Program committee has determined the participant is not qualified to receive alemtuzumab.
    • AddedNOTE: Alemtuzumab (Campath) is no longer distributed commercially. To receive product, the physician must contact the program for the participant. If Campath use is indicated and the participant is not willing to consent to submit their info (demographics, contact information, and rationale for use) to the program such that we can obtain the drug, then the participant will not undergo gene therapy and will be withdrawn.
    + 1 other change: description
  7. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date
  8. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date
  9. Oct 2, 2026
    Minor edits only
    + 1 other change: description
  10. Sep 28, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01306019
Responsible party
Sponsor
First posted
Mar 1, 2011
Start date
Sep 25, 2012
Primary completion
Dec 31, 2032 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Nov 12, 2026

Study contacts

Suk S De Ravin, M.D.
Contact
sderavin@mail.nih.gov
(301) 496-6772
Suk S De Ravin, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alemtuzumab

Start the discussion